Research Archives - Page 3 Of 17

New Law the Beginning of the End of Animal Research?

It’s called a “liver-chip.” Researchers grew human liver cells on a small chip-like device, hoping to use it to predict when a drug might cause liver injury. Not only did it do so — flagging a set of small molecule drugs with known hepatoxicity with 87{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} specificity — but it also outperformed conventional animal models.

In the study, recently reported in Nature, the chip also detected 7 of 8 drugs that had been deemed safe in animal tests but were eventually proven to be toxic to the liver when used clinically.

The researchers, who are primarily with the biotechnology company Emulate, said they believe the use of liver-chips could save an estimated $3 billion annually for the drug industry. They also estimate that adopting the use of four other organ-chip models, which address the most common toxicities that derail products, could generate $24 billion in savings via increased efficiency and productivity.

That type of success may be a harbinger of the future of biomedical research and drug, biologic, and vaccine development. Animal advocates have high hopes that the FDA Modernization Act 2.0, signed into law by President Joseph Biden on December 29, 2022, will speed up the acceptance and use of nonanimal methods, such as the liver chip, for toxicology, safety, and effectiveness testing. For now, the new law only applies to pharmaceuticals, biologics, and vaccines but not devices.

The law allows developers to use nonanimal models, such as cell-based assays, organ chips, organoids, and computer modeling, to prove safety and efficacy during the approval of new drugs. It further removes a requirement for animal studies as part of the process for licensing a biological product that is biosimilar or interchangeable with another biological product.

Theoretically, it’s a big switch. Until now, the FDA has required the testing of products in at least two animal species before it can advance to human trials. It is also the culmination of years of effort to significantly reduce the use of animals in research and development.

Surprisingly, however, it only took a single congressional session to pass the law, which had significant bipartisan support, said Wayne Pacelle, president of Animal Wellness Action, a Washington-based nonprofit that lobbies for animal welfare. “The fact that we essentially got this passed almost unanimously is a watershed,” Pacelle told Medscape Medical News.

He said members of Congress had been influenced by the increasing move away from animal testing in the cosmetics and chemicals industries, where the Environmental Protection Agency (EPA) ordered an end to animal use by 2035.

Pacelle also pointed to what he called a “broadly merging consciousness about animals and their well-being,” whether it be improved welfare for farm animals, the removal of elephants from circuses, or a rejection of leather and fur. “There is a rising tide of consciousness, and the science industry is not immune from that,” said Pacelle.

Animal Research Still Necessary?

However, some researchers — and the FDA — say none of the alternative methods is reliable enough to be used regularly.

An FDA spokesperson told Medscape Medical News that animal research is still necessary in many areas because “current nonanimal methods cannot always predict effects that occur in highly complex interacting systems such as the human body.”

In addition, some say that while it may be possible to decrease the numbers of animals being used, it will never be possible to completely eliminate their use.

“I am a passionate believer in the safe, secure, honorable way of doing research involving animals that does not produce any kind of unacceptable harm to them,” Henry Friedman, MD, chairman of the Foundation for Biomedical Research, a nonprofit group that advocates for animal research, told Medscape Medical News.

“But I’m totally of the belief that the notion there will be a day when we won’t need animal models is absolute nonsense,” added Friedman, who is a pediatric and adult neuro-oncologist and the James B. Powell, Jr, Distinguished Professor of Pediatric Oncology at the Duke University School of Medicine.

Many animal advocates are unyielding. Animal Wellness Action and its sister organization, the Center for a Humane Economy, are calling on the FDA to completely eliminate animal testing from drug development by 2030.

There is a moral and ethical imperative to do so, said John Gluck, PhD, professor emeritus of the University of New Mexico and a faculty affiliate with the Kennedy Institute of Ethics at Georgetown University.

Animals’ “lives aren’t ours,” Gluck told Medscape Medical News. “They have a set of capabilities that are relevant to pursuing a life that has evolved over millions of years,” he said. “We’re taking hold of those capabilities without sufficient respect for those capabilities,” he said.

Although the pharmaceutical and biotechnology industries have been actively developing and using nonanimal models, no one expects any immediate changes where it matters most ― at the FDA.

The law is just “the first step in this entire process,” said Aysha Akhtar, MD, MPH, co-founder and CEO of the Center for Contemporary Sciences, a Gaithersburg, Maryland-based nonprofit that promotes animal alternatives.

“More than anything, this sent a message throughout the entire community that, look, we are ready to start moving on, we are ready to start making a change,” said Akhtar, who was a medical officer at the FDA for 10 years. “It’s not going to happen overnight but is going to start to incentivize the further use of these other methods,” she added.

FDA Slow to Change

FDA has been slow out of the gate, agreed Tamara Drake, director of research and regulatory affairs for the Center for a Humane Economy. “Our biggest resistance in the beginning with this legislation was the FDA,” she told Medscape Medical News.

While Drake said the agency has since made a “turnabout,” it is still moving at what she calls “a snail’s pace” in terms of evaluating nonanimal technologies.

“We don’t believe they are moving with the urgency that’s required to fix this broken drug development paradigm,” she said. The agency plans to evaluate two to four alternatives a year, she said, adding that is not enough when all of the major drug and biotech companies are already employing the technologies.

From the agency’s point of view, the law “does not change the regulatory process for drugs and does not eliminate animal testing,” said an FDA spokesperson, Veronika Pfaeffle. “The FDA will continue to ensure clinical investigations of drugs are reasonably safe for initial use in humans,” she added.

“The amendment does not change the fact that FDA reviewers have wide latitude to tell companies what kind of data they want to see,” said Matthew R. Bailey, president of the National Association for Biomedical Research, a nonprofit that represents 340 universities, medical and veterinary schools, pharmaceutical and biotechnology companies, and professional societies on legislative and regulatory matters pertaining to laboratory animal research.

Bailey also said that manufacturers have long been able to submit nonanimal data to the FDA. The agency will likely want to see animal data for the foreseeable future because neither the FDA nor manufacturers “want to be accused of killing people at the clinical trial stage due to negligence,” Bailey told Medscape Medical News.

Rachael Anatol, senior vice president of science and regulatory affairs at BIO, a trade organization, called the FDA Modernization Act “a step in the right direction.”

However, she said, “It will take some time to see a significant real-world impact. It will be critical for companies to demonstrate to FDA that alternative methods can provide the same assurances as animal models with respect to human safety or tolerability of new drugs and biological products. And for the market to fully shift to nonanimal alternatives, the FDA will need to provide assurance that these new methods will be accepted.”

The agency notes that its budget for fiscal year 2023 includes $5 million to support the New Alternative Methods Program, aimed at encouraging the evaluation, qualification, and acceptance of nonanimal alternatives.

In addition, the FDA may begin to feel more pressure to harmonize with policy and regulations being formulated in Europe. The European Union already prohibits the use of animals in the development of cosmetics, and in September, members of the European Parliament called for an expedited plan to eliminate animals in any research or testing.

95{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} Failure Rate

Many believe animal models are outmoded and are not reliably predictive of what a drug — especially a small-molecule therapeutic — will do when it gets into a human.

“Unfortunately, the way we do small molecules, at least in the pharmacologic area, has been fraught with a lot of failures,” said Danilo A. Tagle, PhD, director of the Office of Special Initiatives at the National Institute of Health’s (NIH’s) National Center for Advancing Translational Sciences (NCATS).

Tagle cites a “90{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} failure rate” of drug candidates on going from screening to use in humans, due mostly to the lack of accurate predictive testing in cell culture and animal models.

The low success rate “adds cost and adds time, and then at the same time it also puts patients at risk,” Tagle told Medscape Medical News. “Even when these drugs are approved for human trials, more often than not, they are found to be either toxic or ineffective,” he said.

NCATS has estimated that the failure rate can be as high as 95{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} and that it costs a minimum of $1 billion to bring a drug to market.

“What that failure rate really means is that 90{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} to 95{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of all drugs and vaccines that have been found safe and effective in the animal tests end up being unsafe or ineffective in humans,” said Akhtar. “That’s a glaring, glaring statistic.”

Using animals as surrogates may have worked 100 years ago, when there was less knowledge, but developers today “are looking at the subtle nuances of molecular physiology, biochemistry, and neurophysiology,” she said. “At this molecular subtle level, even minor differences between species can profoundly impact study results,” Akhtar said.

“For scientific and human health reasons, we should not be using other species to try to understand human biology, because there’s just too many differences between species,” she added

On the other hand, many drugs and vaccines that may have held promise in humans have likely been discarded because they were not safe or effective in animals, said Akhtar, adding that animal models may not represent the most effective use of resources. It all “suggests that there is a lot of room for improvement in drug development process,” she added.

Friedman acknowledges a high failure rate but says a certain winnowing — via animal models — is necessary.

“The notion that animal work doesn’t predict response in humans is in general something you can say, but in some cases, it does predict benefit,” he said.

More importantly, it helps predict toxicity, said Friedman. “I don’t want to kill people. I don’t want to hurt patients with novel therapies. I don’t want to hurt animals either.”

Animal Suffering

The Duke-developed modified poliovirus therapy for glioblastoma could not have happened without the use of long-tailed macaques, said Friedman. “It took a decade to produce the kind of the data that led the FDA to say that it was safe to proceed” to human trials, said Friedman.

The university — like most institutions — keeps close tabs on how many animals it uses, their care, and how they are used, as required by the US Department of Agriculture (USDA), Friedman said.

The USDA requires reporting on how many animals are being held but are not used in research, how many are used for research, and how many are subjected to pain with or without pain relief. These reports are available to the public.

The animals used in research run the gamut from rodents to rabbits, pigs, sheep, dogs, cats, llamas, and nonhuman primates. In fiscal 2019, almost 800,000 animals were used, although this count does not include mice and rats. About 50,000 were subjected to pain but were not given any sort of pain relief.

The England-based nonprofit Fund for the Replacement of Animals in Medical Experiments (FRAME) reports that 3 million experiments were carried out on animals in the United Kingdom in 2021. Of those procedures, 96{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} were carried out on mice, rats, birds, and fish, said FRAME.

Researchers worldwide follow the “three Rs” — which call for the replacement, reduction, and refinement of animal use. While most institutions and companies may do so, horror stories still surface.

In July 2022, the US Department of Justice forced Envigo, a company that breeds and sells animals for research, to surrender some 4000 beagles that had been kept in inhumane conditions in Maryland.

Gluck wonders about the impact of poor animal husbandry or housing conditions that on the surface may seem acceptable but in fact are less than ideal. A rodent living in a typical cage in a typical lab is living in an environment that is 280,000-fold smaller than what it has evolved to live in, said Gluck.

A rhesus monkey is living in a metal mesh cage that is 7-million-fold smaller than the environment it evolved to live in, he said. Aside from the suffering, “what does that do to our science?” said Gluck. Most likely, it distorts the science, he said.

Alternatives on the Horizon

Since its founding a decade ago, the National Center for Advancing Translational Sciences has been looking into how to improve the science of the drug development process, with an eye on creating new efficiencies and, as part of that, reducing or eliminating the use of animals, said Tagle.

NCATS — with a small budget of about $35 to $40 million a year — has been digging deep into tissue chips (also called organs-on-a-chip), computational models, and other technologies in partnership with the FDA, the EPA, NASA, the Department of Defense, and industry and academic partners, said Tagle.

Tissue chips mimic the structure and function of a specific organ and include the heterogeneous collection of every cell in an organ. “We also capture the microenvironment of the tissue,” said Tagle, adding that researchers can subject the chips to stretching or mechanical load.

“Their environment is very similar to what’s happening in the human body,” and the cells are all derived from humans representing a variety of ages, races, genders, and ethnicities, Tagle said.

NCATS has been working with the FDA to validate the chips, and it funded testing centers at the Massachusetts Institute of Technology (MIT) and Texas A&M University. In 2021, under NCATS orders to become self-sustaining, MIT spun off its testing unit into a new start-up, Javelin Biotech, and Texas A&M created the Texas A&M Tissue Chip Validation (TEX-VAL) Consortium.

The NIH center is also funding eight projects that will use tissue chips to identify safety issues early on in human clinical trials and to potentially inform effectiveness. Use of the chips could potentially eliminate the need for a placebo arm, said Tagle.

But the technology is still being polished, he noted. “We’re not at that stage yet where we can practically claim that we have tissue chips that can replace animals. At best, they are a supplement or complementary to animal data, but there will come a time when we can probably say yes, we can replace animals with this technology,” Tagle said

In addition, tissue chips are just one of many animal alternatives being developed. A 2020 study by GlaxoSmithKline researchers, for instance, noted the potential of artificial intelligence (AI) to revolutionize drug discovery.

The report noted that Pfizer, Sanofi, Genentech, and GlaxoSmithKline were employing AI, machine-learning, and deep-learning methods to search for new drug candidates and that the “prediction of hepatotoxicity is one of the most notable areas in which these modeling efforts are being applied.”

Cultural Barriers Persist

Cultural hurdles may prove to be a greater challenge than technologic issues. Most current scientists received training in animal methods, and it becomes a “self-perpetuating paradigm,” said Akhtar. Many younger scientists are coming in with a fresh perspective and may use some of the new tools right from the start, she said.

But efforts to reverse those perspectives may be effective for those in favor of animal research. In 2019, the American Academy of Neurology (AAN) surveyed US-based student members to gauge their attitudes toward animal research. Most of the participants were male, and it was a small survey of 168 students.

The AAN researchers found that after viewing a video suggesting that animal research created multiple benefits for human health, students had a much more positive attitude toward the use of animals. Prior to seeing the video, 4.3{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} agreed with the statement, “animal research cannot be justified and should be stopped,” but after seeing the video, none agreed with that statement, suggesting this “simple educational intervention” might influence attitudes in this “crucial population,” the investigators, led by David Q. Beversdorf, MD, chair of the AAN’s Animal Research Task Force, concluded.

Gluck said that students regularly challenged him on his use of animals in his own research when he was at the University of New Mexico. His faculty was less interested in pursuing the moral or ethical questions, he said. “Getting faculty, including myself at that time, to talk about alternatives to the animals that were a crucial part of our experimental designs just seemed absurd,” said Gluck.

Researchers tended to merge together into a “thought collective,” with those using monkeys attending the same conferences and having the same beliefs about their work, he said. Scientists who worry about tenure are also unlikely to rock the boat and lobby for the use of alternatives, especially when universities have invested heavily in labs and animal care infrastructure, Gluck noted.

“We’ve been stuck in a particular conceptual mode of doing research,” he said. But he believes that change will come as the weight of the evidence for alternatives becomes more robust.

Pacelle said that while it may be unrealistic to demand that no animals be used in drug development, “everyone should agree, including the research industry, that that must be our goal.

“There are moral costs with the use of animals in our society,” he said. “They feel pain, the physical pain, emotional pain of trauma. The only kind of logical rationale is we are sacrificing them for the greater good. But if we can do better and use alternatives, then everyone should be on board with that strategy,” said Pacelle.

Using as few animals as possible is a laudable goal, said Friedman. “But don’t ask me to choose between the rights and the moral obligation to take care of animals compared to the moral obligations to take care of patients,” he said. “I don’t think that’s a choice. My oath is to take care of patients. I’ll do everything I can to help them.”

The study was funded by Merck. Smith has received grant funding from Merck. Jones reports no relevant financial relationships. Gluck consults (without compensation) for various animal advocacy organizations.

Alicia Ault is a Saint Petersburg, Florida-based freelance journalist whose work has appeared in publications including JAMA and Smithsonian.com. You can find her on Twitter @aliciaault.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Ancient DNA as a tool for medical research

The simplest model used to study human susceptibility to infection is genetic predisposition to infectious diseases through inborn errors of immunity — mutations that increase the risk of severe infections⁶. The most successful approach has been to study people who are extremely susceptible to infections, as they have the highest odds of carrying highly penetrant genetic lesions. The main advantage of this approach is that causality between genotype and phenotype follows naturally from the study of an in vivo (human) model, although its implementation requires the extensive genetic screening of severely ill patients.

An alternative approach is to study the effects of natural selection from pathogenic pressure on human genome variability⁷. These two frameworks are comparable in that both involve the identification of variants that increase the risk of a given infectious disease in natura. However, they differ in that inborn errors of immunity usually operate at the scale of a single generation, whereas gradual pathogenic pressure operates at the scale of many generations, which makes it possible to identify genetic variants with effect sizes that differ by several orders of magnitude.

Recent studies have highlighted the value of using ancient genomes from different epochs, known as aDNA time series, to reconstruct the evolutionary history of immune disorders and past epidemics (Fig. 1). One recent proof-of-concept study of more than 1,000 genomes dated to within the last 10,000 years of European history showed that a tuberculosis risk variant, TYK2 P1104A, present in around 3{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of people of European ancestry, has evolved under strong negative selection over the past two millennia⁸. This finding, probably reflective of the pressure imposed by Mycobacterium tuberculosis, would have been very difficult to achieve through studies of modern DNA. Indeed, most methods for detecting natural selection in modern DNA data are underpowered for low-frequency variants.

**Fig. 1: Ancient DNA can identify genetic variants associated with disease risk.**

The evolutionary history of the pathogen itself can also provide insight into the dynamics of past epidemics, but this was difficult to characterize until samples from ancient pathogens became available. In the context of tuberculosis, studies of ancient mycobacteria have dated the most recent common ancestor of the pathogen to only 6,000 years ago, which contrasts markedly with the estimates of more than 70,000 years ago that were obtained from studies of modern strains of M. tuberculosis⁹. Medical practitioners may find aDNA studies similarly helpful for pinpointing genetic variants of microorganisms, as their evolutionary history can reveal their deleteriousness to human health.

aDNA time series at the scale of the entire human genome can identify variants under negative selection, which is useful for the detection of new genetic factors associated with immune disorders, as described in a recent study¹⁰. Paleogenomics therefore appears to be a powerful approach, complementary to epidemiological and clinical genetics studies, that can be used to confirm and expand on genetic variants associated with disease risk.

AI language models open a potential Pandora’s box of medical research fraud

Medical student and researcher Faisal Elali of the State University of New York Downstate Health Sciences University and medical scribe and researcher Leena Rachid from the New York-Presbyterian/Weill Cornell Medical Center wanted to see if artificial intelligence could write a fabricated research paper and then investigate how best to detect it.

Artificial intelligence is an increasingly valuable and vital part of scientific research. It is used as a tool to analyze complicated data sets, but it is never used to generate the actual paper for publication. AI-generated research papers, on the other hand, can look convincing even when based on an entirely fabricated study. But exactly how convincing?

In a paper published in the open-access journal Patterns, the research duo demonstrated the feasibility of fabricating a research paper using ChatGPT, an AI-based language model. Simply by asking, they were able to have ChatGPT produce a number of well-written, entirely made-up abstracts. A hypothetical fraudster could then submit these fake abstracts to multiple journals seeking publication. If accepted, the same process could be used to write an entire study with false data, nonexistent participants and meaningless results. However, it could appear legitimate, especially if the subject is particularly abstract or not screened by an expert in the specific field.

In a previous experiment cited in the current paper, humans were given both human-created and AI-generated abstracts to consider. In that experiment, humans incorrectly identified 32{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of the AI-generated research abstracts as real and 14{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of the human-written abstracts as fake.

The current research team decided to test their ChatGPT fabricated study against three online AI detectors. The texts were overwhelmingly identified as AI-generated, suggesting the adoption of AI detection tools by journals could be a successful diverter of fraudulent applications. However, when they took the same text and ran it through a free, online, AI-powered rephrasing tool first—the consensus unanimously flipped to “likely human,” suggesting we need better AI detection tools.

Actual science is hard work, and communicating the details of that work is a crucial aspect of science requiring substantial effort. But any mostly hairless ape can string sensible sounding words together given enough time and coffee—as the writer of this article can firmly attest. Creating a fake study with enough detail to seem credible would take tremendous effort, requiring hours of researching how best to sound believable, and might be too tedious a task for someone interested in malicious mischief. With AI completing the task in minutes, that mischief could become an entirely achievable objective. As the researchers point out in their paper, that mischief could have terrible consequences.

They give an example of a legitimate study that supports the use of drug A over drug B for treating a medical condition. Now, suppose a fabricated study makes the opposite claim and is not detected (as a side note, even if it is detected, clawing back citations and reprints of retracted studies is notoriously difficult). It could impact subsequent meta-analyses and systematic reviews of these studies—studies that guide health care policies, standards of care and clinical recommendations.

Beyond the simple mischief motive, the authors of the paper point to the pressure on medical professionals to quickly produce a high volume of publications to gain research funding or entry into higher career positions. In part, they point out that the United States Medical Licensing Examination recently switched from a graded exam to a pass/fail model, meaning ambitious students rely more heavily on published research to distinguish them from the pack. This raises the stakes for a trustworthy AI detection system to remove potentially fraudulent medical research that could pollute the publishing environment—or worse still, practitioners who submit fraudulent papers from practicing on patients.

The goal of AI language models has long been to produce texts that are indistinguishable from human text. That we need AI that can detect when a human is using AI to produce fraudulent work indistinguishable from reality should not come as a surprise. What might be surprising is just that we may need it so soon.

More information:
Faisal R. Elali et al, AI-generated research paper fabrication and plagiarism in the scientific community, Patterns (2023). DOI: 10.1016/j.patter.2023.100706

Citation:
AI language models open a potential Pandora’s box of medical research fraud (2023, March 14)
retrieved 14 March 2023
from https://medicalxpress.com/news/2023-03-ai-language-potential-pandora-medical.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Medicaid Clinical Research Coverage Update | Ankura

On January 1, 2022, the new Medicaid research coverage regulation went into influence. The rule is portion of the H.R. 133 – The Consolidated Appropriations Act. The Medicaid exploration protection info is discovered in SEC. 210. Promoting Obtain TO Lifestyle-Saving THERAPIES FOR MEDICAID ENROLLEES BY Ensuring Protection OF Regime Affected person Fees FOR Goods AND Solutions FURNISHED IN Relationship WITH PARTICIPATION IN QUALIFYING Medical TRIALS. The rule calls for just about every state Medicaid to address certain charges related with sure medical trials. See for a much more in-depth overview of the precise necessities and likely operational problems. The New Medicaid Scientific Investigation Coverage Regulation: What you Want to Know and Do Now, Sarah Couture (ankura.com) for a much more in-depth overview of the unique specifications and probable operational difficulties.

Whilst most states have now amended their point out plans to protect required medical analysis solutions, very handful of state Medicaid programs have offered advice to provider businesses with regards to operationalizing the rule, including instructions for submitting the demanded attestation form (medicaid-attest-form.docx (are living.com)). Other concerns abound from companies linked to the rule by itself. In their State Prepare Amendments (SPA), states could have clarified certain phrases or protection ways, but most have adopted the language of the rule itself which poses considerable issues:

What constitutes a “serious or lifetime-threatening” ailment or situation?
Is typical treatment protected similar to Medicare protection (for each NCD 310.1)?
How is the rule used to gadget scientific studies?

As states finalize their SPAs and condition Medicaids establish their precise approaches for the attestation and other compliance expectations, provider companies keep on to battle with the deficiency of clarity and subsequent issues in operationalizing the necessities. We keep on to advise the subsequent:

Stay informed as condition Medicaid strategies build and roll out their methods, which include achieving out to those options for assistance on the procedure
Advocate with point out legislatures regarding problems and problems that might be impacting people or the corporation
Proceed doing a Medicare-primarily based coverage investigation, then overlay Medicaid particulars
Continue on demanding indigency clauses in sponsor contracts as not all studies will be qualifying, and not all expert services within just a qualifying examine will be billable

This write-up was co-authored with Cassie Cruz-Montez, MHA, YCCI Exploration Billing Compliance Analyst, Yale College of Medication, Yale Centre for Scientific Investigation.

Research literacy bridges the medical mistrust gap

A extended inglorious background of clinical racism and mistreatment has dire overall health penalties. Think about the atrocities linked with experimentation on African Us citizens without informed consent in the course of the Tuskegee Syphilis Research (1932-1972), which eroded the believe in in the health-related profession and healthcare exploration, and undermined the nation’s ability to obtain wellbeing fairness.

Professional medical mistrust proceeds to worsen because of to the detrimental wellbeing treatment ordeals African Us residents nonetheless endure today. For example, for the duration of the first rollout of the coronavirus vaccine, some African Individuals cited weak procedure by professional medical providers and well being care institutions as a purpose not to get vaccinated. This menace to vaccine equity is disturbing, offered that African Americans and other men and women of colour continue to be at an amplified possibility for COVID-19 infection, hospitalization, and loss of life.

This extensive legacy of structural racism and healthcare mistrust threatens the nation’s means to ensure that African Americans advantage from health care breakthroughs in analysis and obtain novel prevention or therapy modalities.

The mistreatment of African Americans within the professional medical program, compounded by the deficiency of basic investigate know-how, allows gas considerably of this distrust. A essential part to developing and sustaining health-related trust and addressing inequities is guaranteeing better analysis literacy among the African People in america. As wellbeing care pros with skills in wellness care and well being communications, we have furnished credible wellness info to clients and people. For the reason that of our proximity to patients, we have witnessed firsthand the perils of remaining misinformed or uninformed about wellbeing-associated issues, together with professional medical exploration.

Although it is really hard to know what percentage of African People are analysis literate, we know that weak personal overall health literacy can perpetuate wellbeing disparities and bad overall health outcomes. Some men and women with decreased health literacy are at an greater possibility of not becoming equipped to navigate the wellbeing care procedure, connect correctly with providers or adhere to health care suggestions. Low well being literacy can also influence an individual’s means to fully grasp the exploration process or make an knowledgeable selection irrespective of whether to take part or not participate in any study.

To complicate matters even more, while Black People in america have some confidence in experts, in one examine as lots of as 61 per cent of respondents noted getting anxious about exploration misconduct and accountability. This lack of trust and self confidence in research accountability, along with insufficient exploration literacy results in the fantastic storm for the ongoing absence of illustration by traditionally marginalized folks in scientific analysis and ongoing COVID vaccination initiatives.

Knowing the heritage of health-related mistreatment is even now a key component of healthcare distrust but can serve as a barrier to development. The concentrate needs to shift to ways researchers stop any exploration misconduct and make certain the defense of all human subjects.

Small gains in investigation literacy are being produced with systems this kind of as All of Us from the Nationwide Institutes of Well being, which performs to develop a database of health knowledge from a diverse team of individuals to speed up research and investigate participation. What makes the method special is that participants have total access to the data they share and know about all the tasks that use this knowledge.

Some African Americans discover about research by taking part in local community-based participatory analysis assignments or serving as science citizens for investigation companies or as research team associates. This is a excellent start out, but researchers and stakeholders must do more to assure analysis literacy and transparency.

Any effort to reinforce research literacy should take into account these and other things identified to influence an individual’s means to obtain, understand, and use all types of overall health information and facts. As advocates simply call for enhanced health and fitness literacy, we will need a sturdy target on analysis literacy now and over and above the COVID-19 crisis.

The lack of a strong foundation of study literacy compromises Black Americans’ skill to make sound health conclusions about issues like exploration participation and other wellness problems.

To tackle this urgent problem, scientists and analysis businesses ought to give options for African Americans to study about investigate just before initiating recruitment attempts. This could be a ingredient of health and fitness-connected community outreach endeavors doing the job to access this population. Proposals for exploration funding should include things like ways to improve analysis literacy as correct. This sort of attempts really should include things like a aim on the progress in the defense of human topics. These improvements include things like a more robust emphasis on transparency via educated consent, greater investigator oversight and accountability, and much more stringent polices. This is specifically crucial for members of the African American local community who are influenced by prior study cruelties.

Investigate literacy could enable assistance the final decision-creating process of African People by dispelling the myths involved with the present vaccine rollout and furnishing much more assurances pertaining to the rigors connected with drug enhancement and other scientific breakthroughs. New initiatives to advance investigate from this perspective are critical to disrupting the cycle of underrepresentation of African People in america in medical analysis and increasing the utilization of scientific breakthroughs by these most in need.

Ensuring exploration literacy is a ought to for attaining wellness fairness. Anything at all a lot less has the probable to perpetuate the ongoing health and fitness disparities and wellbeing inequities that have plagued communities of shade for generations.

Janice Phillips is a nurse and community coverage advocate. Nikki Hopewell is a journalist.

The Role of Retail Pharmacies in the Evolving Landscape of Clinical Research

The Role of Retail Pharmacies in the Evolving Landscape of Clinical Research
The world of clinical research is constantly evolving, and one of the most significant shifts in recent years has been the entrance of retail pharmacies into the space. Companies like CVS, Walgreens, Walmart, and Kroger have become leaders in retail clinical research, offering patients more convenient access to clinical trials. However, while these companies benefit the clinical research space, there are some concerns.

CVS has emerged as a leader in the retail clinical research space, with around 100 Minute Clinics that can support clinical research, and has extensive patient and claims data, which can be used to conduct outreach to patients interested in participating in clinical research, and support protocol optimization. The convenience of these locations makes clinical research more accessible to patients, especially those living far from academic medical centers and lacking easy access to clinical trials.

The emergence of retail pharmacies has the potential to make clinical trials more diverse and accessible. These companies can help recruit more diverse and local patient populations by reaching out to patients directly, which is critical as clinical trial populations have historically been skewed toward specific demographics and supplement patient diversity by going global rather than ensuring local patient representation. Additionally, real-world evidence data from pharmacies can be used to design more thorough protocols and studies; biopharmaceutical companies are analyzing patient data using machine learning algorithms to design better studies.

However, despite the potential benefits of retail pharmacy clinical research, patient participation in clinical trials remains low, with only 3{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of patients participating in trials (as mentioned by Debbie Profit, Vice President, Clinical Management and Applied Innovation at Otsuka Pharmaceuticals at SCOPE). One of the reasons for this is the inconvenience of clinical trials, with patients having to take time off work, travel to the clinic, and deal with other burdensome requirements. To address this, the industry must focus on making clinical trials more convenient for patients by offering remote participation options and flexible scheduling.

Josh Rose, VP, Head of Clinical Trial Delivery, Site Solutions, and Strategy at CVS, presented the results of a survey CVS conducted on patients at SCOPE 2023, indicating that patients prefer decentralized clinical trial methods, such as having a study site close to their homes, appointment flexibility, and telehealth study visits.

Sid Jain Johnson, Head, Global Development Data Science Strategy & Portfolio at Janssen, emphasized the industry’s recognition of patient burden and the need for change at SCOPE. He shared his experience driving an hour each way to see a specialist and how it deters him from participating in trials. He believes that the industry is acknowledging this challenge and working towards making clinical trials more patient-centered.

Another potential benefit of retail pharmacies in the clinical research space is the ability to offer more personalized care to patients. Retail pharmacists are often the first point of contact for patients seeking medical advice and can play a critical role in identifying potential clinical trial candidates. By working closely with clinical trial teams, retail pharmacists can help ensure patients receive the necessary information and support to participate in clinical trials. This personalized approach to patient care can help build trust and improve patient outcomes, ultimately benefiting the entire healthcare system.

The role of retail pharmacies in the evolving landscape of clinical research is not without controversy. For example, the fact that these enterprises are new at clinical trials brings clinical trial quality oversight and data quality concerns that could compromise the safety and efficacy of new treatments. There are also concerns about potential conflicts of interest, as retail companies have a financial stake in revenue generation since they’re publicly held and may compromise patient safety or data quality for financial gain; alternatively, privately-held study sites may focus less on finances and more on conducting quality clinical trials. While retail pharmacies can help recruit diverse patient populations, barriers to participation still need to be addressed, such as patient burden and the inconveniences stemming from poor protocol design, a sponsor’s responsibility.

In summary, retail pharmacies like CVS, Walgreens, Walmart, and Kroger have the potential to transform the clinical research industry by offering more convenient access to clinical trials and helping to recruit diverse patient populations. However, the industry must address the patient burden by providing more convenient and accessible options to increase patient participation. The quality of data collected in these settings and potential conflicts of interest must also be addressed to ensure patient safety and data integrity. By doing so, clinical trials can become more representative of the patient population, leading to better treatments and medications.

Moe Alsumidaie, MBA, MSF, is a thought leader and expert in the application of business analytics toward clinical trials, and regular contributor to Applied Clinical Trials.